Net profit of Emergent BioSolutions under GAAP for 9 months of 2020 amounted to $119.7 million, having increased 16 times from $7.6 million in the previous year. Revenue increased by 30.4% to $972.4 million, against $745.7 million a year earlier.
Net profit of Emergent BioSolutions under GAAP for 9 months of 2020 amounted to $119.7 million, having increased 16 times from $7.6 million in the previous year. Revenue increased by 30.4% to $972.4 million, against $745.7 million a year earlier. 
investors.emergentbiosolutions.com
English (US) 